Androgen-regulated pmepa1 gene and methods of using the same to inhibit cancer cell growth
CA 2485138 C · Owner: Xu, Linda L. · Inventors: Moul, Judd W.; Xu, Linda L.; Srivastava, Shiv
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to an androgen-regulated gene PMEPA1, and proteins , encoded by this gene including variants and analogs thereof. Methods of inhibiting cancer cell growth, reducing androgen receptor expression modulating the expression of genes that are transcriptionally regulated by androgen receptor, and diagnosing and/or prognosing prostate cancer are also provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 9, 2003 and granted April 28, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 9, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 9, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.